JP MORGAN/CALL/EDWARDS LIFESCIENCES/120/0.1/17.01.25 | Market Closed - Börse Stuttgart 03:58:50 2024-06-14 EDT | ||
| 0.083 EUR | -3.49% |
|
| Current month | -10.75% | ||
| 1 month | +16.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 0.083 | -3.49% |
| 24-06-13 | 0.086 | +3.61% |
| 24-06-12 | 0.083 | +15.28% |
| 24-06-11 | 0.072 | -25.00% |
| 24-06-10 | 0.096 | +7.87% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 03:58 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JL1J22 |
| ISIN | DE000JL1J220 |
| Date issued | 2023-04-06 |
| Strike | 120 $ |
| Maturity | 2025-01-17 (216 Days) |
| Parity | 10 : 1 |
| Emission price | 0.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.75 € |
|---|---|
| Lowest since issue | 0.047 € |
| Spread | 0.086 € |
| Spread % | 50.59% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.29
USD
Average target price
96.24
USD
Spread / Average Target
+10.25%
- Stock Market
- Warrants
- Warrant
